Director Rhea J. Posedel executed a sale of 15,000 shares of common stock in Aehr Test Systems (NASDAQ: AEHR) on April 16, 2026, at $80.72 per share, producing proceeds of approximately $1.21 million. The disposal was recorded in a Form 4 filing with the Securities and Exchange Commission. At the time of the transaction the stock was trading near $80.85, following an 891% increase over the past 12 months.
The filing shows Posedel retains direct ownership of 71,163 shares, a figure that includes shares that remain subject to unvested restricted stock units. She also has an indirect interest through a trust holding 411,979 shares. The sale reduces her immediate direct stake while leaving substantial direct and indirect holdings in place.
Market commentary included in the public record notes that, according to InvestingPro analysis, the stock appears overvalued at current levels. That analysis highlights a high revenue valuation multiple despite ongoing profitability challenges for the company.
Operationally, Aehr Test Systems disclosed a sizable production order valued at $41 million from a hyperscale customer. The purchase is for the package-level burn-in of custom AI processor ASICs and encompasses Sonoma high-power package-level test and burn-in systems, burn-in modules, and device-specific sockets. Deliveries for the order are scheduled to begin in the company’s fiscal 2027.
Financial results for Q3 2026 were mixed. The company reported earnings per share of -$0.05, which exceeded the expected -$0.07. Revenue for the quarter was $10.3 million, which came in below the forecast of $10.8 million. Offsetting the revenue shortfall, Aehr achieved record quarterly bookings of $37.2 million and reported a backlog that exceeds $50 million.
Analyst responses to these developments were varied but tilted toward optimism on demand. Freedom Broker raised its price target to $61 from $38 while maintaining a Hold rating. Lake Street increased its target to $56 from $50 and kept a Buy rating, citing strong booking momentum.
Taken together, the insider sale, the large hyperscale order with deliveries beginning in fiscal 2027, the mixed quarterly results and the analyst target increases describe a company experiencing a meaningful shift in demand metrics even as valuation and profitability remain areas of scrutiny. The transaction by a director, the reported backlog and the announced production order are likely to be watched closely by investors monitoring execution, revenue realization and margin dynamics going forward.